Topic: respiratory diseases
Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
GlaxoSmithKline may exit the respiratory business and pull back in other areas to commit more cash to cancer R&D.
Bayer and Evotec partner Haplogen will work to identify new treatments, such as antivirals, for pulmonary diseases.
The series B round comes six months after ReViral completed a phase 2a evaluation of RSV fusion inhibitor RV521 in healthy volunteers.
Propeller Health and Aptar Pharma partner up to digitize drug delivery and offer a platform for pharma companies to track and manage patient usage.
Shares in Faron are in free fall this morning after a phase 3 trial of its lead drug Traumakine for acute respiratory distress syndrome failed.
The deal sees AstraZeneca join Novartis among Mereo’s shareholders and further its efforts to offload deprioritized drugs.
Propeller Health is launching an API, as well as a series of tools based on it, that provides information on local asthma conditions.
Acceleron's collaboration with Celgene on sotatercept has taken another turn, giving Acceleron the right to develop the drug for pulmonary diseases.
A first-in-class therapy developed by AstraZeneca and Amgen looks like a strong treatment candidate for severe uncontrolled asthma, according to a respiratory specialist.